Elfetabart Drozuntecan clinical trials
Also written DB-1311 and BNT324.
How each study uses Elfetabart Drozuntecan is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Elfetabart Drozuntecan studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
3 studies that test it; most in 2023 (1)
| Year | Studies |
|---|---|
| 2023 | 1 |
| 2025 | 1 |
| 2026 | 1 |
Who runs them
Industry 3 · Other 0
BioNTech SE (2) · DualityBio Inc. (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses Elfetabart Drozuntecan is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid TumorsRecruitingPhase 1/2DualityBio Inc.NCT05914116Written as DB-1311
- A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate CancerRecruitingPhase 3BioNTech SENCT07365995Written as BNT324
- A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung CancerRecruitingPhase 1/2BioNTech SENCT06892548Written as BNT324